Antiandrogens
Aspirin
Bromhexine
Budesonide
Cannabidiol
Casirivimab/i..
Colchicine
Conv. Plasma
Curcumin
Diet
Ensovibep
Exercise
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Melatonin
Metformin
Molnupiravir
Nigella Sativa
Nitazoxanide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Proxalutamide
Quercetin
Remdesivir
Sleep
Sotrovimab
Vitamin A
Vitamin C
Vitamin D
Zinc

Other
Feedback Home
Home   COVID-19 treatment studies for Colchicine  COVID-19 treatment studies for Colchicine  C19 studies: Colchicine  Colchicine   Select treatmentSelect treatmentTreatmentsTreatments
Antiandrogens (meta) Lactoferrin (meta)
Aspirin (meta) Melatonin (meta)
Bamlaniv../e.. (meta) Metformin (meta)
Bebtelovimab (meta) Molnupiravir (meta)
Bromhexine (meta) N-acetylcys.. (meta)
Budesonide (meta) Nigella Sativa (meta)
Cannabidiol (meta) Nitazoxanide (meta)
Casirivimab/i.. (meta) Paxlovid (meta)
Colchicine (meta) Peg.. Lambda (meta)
Conv. Plasma (meta) Povidone-Iod.. (meta)
Curcumin (meta) Probiotics (meta)
Diet (meta) Proxalutamide (meta)
Ensitrelvir (meta) Quercetin (meta)
Ensovibep (meta) Remdesivir (meta)
Exercise (meta) Sleep (meta)
Famotidine (meta) Sotrovimab (meta)
Favipiravir (meta) Tixagev../c.. (meta)
Fluvoxamine (meta) Vitamin A (meta)
Hydroxychlor.. (meta) Vitamin C (meta)
Iota-carragee.. (meta) Vitamin D (meta)
Ivermectin (meta) Zinc (meta)
Other Treatments Global Adoption
All Studies   Meta Analysis
▶
▶
All Studies   Meta Analysis   Recent: 
0 0.5 1 1.5 2+ Mortality 80% Improvement Relative Risk ΔSHOCS-COVID 50% primary SHOCS-COVID 71% NEWS-2 67% Hospitalization time 26% c19colchicine.com Mareev et al. Colchicine for COVID-19 LATE TREATMENT Favors colchicine Favors control
Mareev, 43 patient colchicine late treatment study: 50% improved recovery [p=0.06] and 26% shorter hospitalization [p=0.08] https://c19p.org/mareev2
copied to clipboard
Proactive anti-inflammatory therapy with colchicine in the treatment of advanced stages of new coronavirus infection. The first results of the COLORIT study
Mareev et al., Kardiologiia, doi:10.18087/cardio.2021.2.n1560
28 Feb 2021    Source   PDF   Share   Tweet
Small trial with 21 colchicine patients and 22 control patients in Russia, showing improved recovery with treatment. The trial was originally an RCT, however randomization to the control arm was stopped after 5 patients, and 17 retrospective patients were added for comparison.
risk of death, 79.6% lower, RR 0.20, p = 0.49, treatment 0 of 21 (0.0%), control 2 of 22 (9.1%), NNT 11, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm).
ΔSHOCS-COVID, 50.0% lower, RR 0.50, p = 0.06, treatment 21, control 22, ΔSHOCS-COVID score, primary outcome.
SHOCS-COVID, 71.4% lower, RR 0.29, p = 0.002, treatment 21, control 22, SHOCS-COVID score.
NEWS-2, 66.7% lower, RR 0.33, p = 0.06, treatment 21, control 22, NEWS-2 score.
hospitalization time, 25.7% lower, relative time 0.74, p = 0.08, treatment 21, control 22.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Mareev et al., 2/28/2021, retrospective, Russia, Europe, peer-reviewed, 21 authors.
All Studies   Meta Analysis
This PaperColchicineAll
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are both valuable and complementary. All practical, effective, and safe means should be used. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases mortality, morbidity, collateral damage, and the risk of endemic status. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit    
Share
Tweet
@CovidAnalysis
FAQ
Public domain CC0 1.0